Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular OutcomesRohan Khera, Patrick B. Ryan, Tara V. Anand et al.|Journal of the American College of Cardiology|2024Cited by 33
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Marc A. Suchard, Michael B. Cook et al.|BMJ Medicine|2023Cited by 27
Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological DesignsMartijn J. Schuemie, Marc A. Suchard, Evan Minty et al.|Frontiers in Pharmacology|2022Cited by 19
Bias, Precision and Timeliness of Historical (Background) Rate Comparison Methods for Vaccine Safety Monitoring: An Empirical Multi-Database AnalysisXintong Li, Daniel Prieto‐Alhambra, Evan Minty et al.|Frontiers in Pharmacology|2021Cited by 13
Vaccine safety surveillance using routinely collected healthcare data – An empirical evaluation of epidemiological designsMartijn J. Schuemie, Marc A. Suchard, Xintong Li et al.|medRxiv|2021Cited by 8